BRIEF RESEARCH REPORT
Published on 17 May 2024
Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
doi 10.3389/fonc.2024.1352281
- 2,110 views
- 2 citations
- Frontiers in Oncology
- Hematologic Malignancies
- Research Topics
- Novel Agents for Multiple Myeloma Vol. II
Novel Agents for Multiple Myeloma Vol. II
4,468
Total downloads
14k
Total views and downloads
Articles
ORIGINAL RESEARCH
Published on 18 Mar 2024
Prognostic significance of β2-microglobulin decline index in multiple myeloma
doi 10.3389/fonc.2024.1322680
- 1,200 views
- 1 citation
REVIEW
Published on 04 Mar 2024
Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells
doi 10.3389/fphar.2024.1351565
- 1,575 views
- 2 citations
SYSTEMATIC REVIEW
Published on 28 Feb 2024
Efficacy and safety of bispecific antibodies therapy for relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials
doi 10.3389/fimmu.2024.1348955
- 3,192 views
- 3 citations
SYSTEMATIC REVIEW
Published on 25 Jan 2024
Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review
doi 10.3389/fonc.2024.1286029
- 2,464 views
- 2 citations
BRIEF RESEARCH REPORT
Published on 06 Dec 2023
Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma
doi 10.3389/fonc.2023.1271847
- 1,625 views
- 2 citations
Published in
Frontiers in Oncology
Hematologic Malignancies
Pharmacology of Anti-Cancer Drugs
Participating Journals
Frontiers in Pharmacology
- 4.4 impact factor
- 7.8 citescore